Vladimir A. Kozlov
USSR Academy of Medical Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Vladimir A. Kozlov.
Journal of Gastroenterology | 2002
Sergey V. Sennikov; Vladimir V. Temchura; Vladimir A. Kozlov; Valeriy A. Trufakin
Background: The aim of this work was to study the influence of soluble factors produced by native mouse intestinal epithelial cells (IECs) on the proliferative activity of freshly isolated intestinal crypt cells. Methods: The crypt cells were cultured with either conditioned medium and its ultrafiltrates or recombinant mouse granulocyte-macrophage colony-stimulating factor (GM-CSF) in the presence or absence of neutralizing anti-GM-CSF antibodies. GM-CSF in culture medium was identified by the electrochemiluminescence method. Results: It was demonstrated that the IEC conditioned medium contained GM-CSF. This cytokine led to both the upregulation and downregulation of crypt cell proliferative activity, depending on its concentration in the culture medium. The effect of native GM-CSF was reproduced with recombinant mouse GM-CSF: 25 and 5u2009ng/ml inhibited the proliferative activity, whereas 1u2009ng/ml led to its significant stimulation. Conclusions: Freshly isolated murine IECs produce GM-CSF, which plays a critical role in crypt cell proliferative activity in vitro. These results suggest the involvement of this factor in the regulation of the crypt proliferative zone, in an autocrine and/or paracrine manner.
Cellular Immunology | 1990
Vladimir A. Kozlov; Alexander Poveshchenko; Natali Gromykhina
The cellular mechanisms involved in the immunosuppressive effect of prostaglandin E2 (PGE2) multiple injections into (CBA x C57Bl)F1 mice in vivo have been studied. PGE2 injection increases the induction of specific T-suppressors. In addition, there is a decrease in macrophage phagocytic activity and in the phagocytosis index, apparently mediated by Fc gamma receptors (Fc gamma R) and not by the macrophage complement receptor (C3R). The induction of antibody synthesis by using immune macrophages injected into a syngeneic recipient results in considerable decrease in the accumulation of antibody-forming cells if the macrophage donor has been pretreated with exogenous PGE2 in comparison with untreated controls. These cellular mechanisms are possibly one part of the diverse way in which PGE2 exerts an immunosuppressive effect in vivo and contributes to humoral immune response suppression.
Immunobiology | 1998
Victor I. Seledtsov; G. V. Seledtsova; D. M. Samarin; Vadim Ya. Taraban; Sergey V. Sennikov; Vladimir A. Kozlov
Nucleated erythroid cells (NEC) have been previously reported to the capable of suppressing antibody-mediated primary (IgM) and secondary (IgG) immune responses to thymus-dependent antigens. In the present study we indicated that NEC, separated from the spleens of mice following phenylhydrazine treatment were able to suppress directly the proliferative response of preactivated B cells to lipopolysaccharide (LPS) in vitro. While being active in suppressing B cell blastogenesis, NEC, however, failed to reduce both cell proliferation and cytotoxic T lymphocyte (CTL) generation in an allogeneic mixed lymphocyte culture (MLC). NEC also lacked a significant effect on interleukin (IL)-2 production and utilization by concanavalin A (Con A)-activated T lymphocytes. The NEC-derived suppression of B cell proliferation was, at least in part, mediated by soluble molecules. The specific blockade of transforming growth factor (TGF)-beta synthesis with antisense oligodeoxynucleotides (OD) binding TGF-beta mRNA, as well as the neutralization of TGF-beta activity with anti-TGF-beta antibodies (Ab), resulted in a detectable diminished ability of the NEC-conditioned medium (CM) to suppress B cell blastogenesis. Taken together, the results suggest that: 1) NEC may suppress directly B cell responses, while not affecting T cell ones; 2) NEC may mediate their natural suppressor (NS) activity partially through releasing TGF-beta.
BMC Cell Biology | 2004
Sergey V. Sennikov; Tatyana V Injelevskaya; Sergey V. Krysov; Alexandr N. Silkov; Igor B Kovinev; Natalya J Dyachkova; Anton N Zenkov; Mary I Loseva; Vladimir A. Kozlov
BackgroundErythroid nuclear cells (ENC) of the bone marrow (BM) have not previously been considered as important producers of wide spectrum of haemo- and immunoregulatory cytokines. The aim of the current work was to confirm the production of the main hemo- and immunoregulatory cytokines in human ENC from BM.ResultsWe used native human BM ENC in our experiments. We for the first time have shown, that the unstimulated erythroblasts (Gl A+ or AG-EB+) produced a wide spectrum of immunoregulatory cytokines. Human BM ENC produce cytokines such as interleukn (IL)-1β, IL-2, IL-4, IL-6, interferon (IFN)-γ, transforming growth factor (TGF)-β1, tumor necrosis factor (TNF)-α and IL-10. They can be sub-divided into glycophorin A positive (Gl A+) and erythroblast antigen positive (AG-EB+) cells. To study potential differences in cytokine expression between these subsets, ENC were isolated and purified using specific antibodies to Gl A and AG-EB and the separated cells were cultivated for 24 hours. The cytokine contents of the supernatant were measured by electrochemiluminescence immunoassay. Quantitative differences in TGF-β1 and TNF-α production were found between Gl A+ and AG-EB+ BM ENC. Furthermore, in vitro addition of erythropoietin (EPO) reduced IFN-γ and IL-2 production specifically by the AG-EB+ ENC. Thus, Gl A+ and AG-EB+ ENC produce IL-1β, IL-2, IL-4, IL-6, IFN-γ, TGF-β1 and TNF-α. Gl A+ ENC also produce IL-10.ConclusionCytokine production by erythroid nuclear cells suggests that these cells might be involved in regulating the proliferation and differentiation of hematopoietic and immunocompetent cells in human BM.
Arthritis Research & Therapy | 2017
Elena Y. Rykova; Aleksey Sizikov; Dirk Roggenbuck; Oksana Antonenko; L. O. Bryzgalov; Evgeniy S. Morozkin; Kseniya Skvortsova; Valentin V. Vlassov; Pavel P. Laktionov; Vladimir A. Kozlov
BackgroundEarly diagnosis of rheumatoid arthritis (RA) is crucial to providing effective therapy and often hampered by unspecific clinical manifestations. Elevated levels of extracellular circulating DNA (cirDNA) in patients with autoimmune disease were found to be associated with etiopathogenesis. To our knowledge, this is the first study to investigate the putative diagnostic use of cirDNA in RA and its association with disease activity.MethodsBlood samples were taken from 63 healthy subjects (HS) and 74 patients with RA. cirDNA was extracted from plasma and cell surface-bound cirDNA fractions (csbDNA). cirDNA concentration was measured by quantitative real-time polymerase chain reaction. Rheumatoid factor was analyzed by immunonephelometry, whereas C-reactive protein and anticitrullinated protein/peptide antibodies (ACPA) were detected by enzyme-linked immunosorbent assay.ResultsPlasma cirDNA was significantly elevated in patients with RA compared with HS (12.0 versus 8.4xa0ng/ml, pu2009<u20090.01). In contrast, nuclear csbDNA (n-csbDNA) was significantly decreased (24.0 versus 50.8xa0ng/ml, pu2009<u20090.01), whereas mitochondrial csbDNA (m-csbDNA) was elevated (1.44u2009×u2009106 copies/ml versus 0.58u2009×u2009106 copies/ml, pu2009<u20090.05) in RA. The combination of csbDNA (mitochondrialu2009+u2009nuclear) with ACPA reveals the best positive/negative likelihood ratios (LRs) for the discrimination RA from HS (LR+ 61.00, LR− 0.03) in contrast to ACPA (LR+ 9.00, LR− 0.19) or csbDNA (LR+ 8.00, LR− 0.18) alone.ConclusionsNuclear and mitochondrial cirDNA levels in plasma and on the surface of blood cells are modulated in RA. Combination of cirDNA values with ACPA can improve the serological diagnosis of RA.
Mediators of Inflammation | 2015
Alina A. Alshevskaya; Julia A. Lopatnikova; Nadezhda S. Shkaruba; Oksana A. Chumasova; Aleksey Sizikov; Aleksander V. Karaulov; Vladimir A. Kozlov; Sergey V. Sennikov
IL-1β is involved in the induction and maintenance of chronic inflammation in rheumatoid arthritis (RA). Its activity is regulated and induced by soluble and membrane-bound receptors, respectively. The effectiveness of the cytokine depends not only on the percentage of receptor-positive cells in an immunocompetent subset but also on the density of receptor expression. The objective of this study was to investigate the expression of IL-1β membrane-bound receptors (IL-1R1 and IL-1R2) in terms of the percentage of receptor-positive cells and the number of receptors per cell in different subsets of immune cells in RA patients before and after a course of basic (excluding anticytokine) therapy and in healthy individuals. The resulting data indicate differences in the expression of IL-1β receptors among T cells, B cells, and monocytes in healthy volunteers and in rheumatoid arthritis patients. The importance of determining both the relative percentage of cells expressing receptors to immunomodulatory cytokines and the number of membrane-bound receptors per cell is highlighted by evidence of unidirectional or multidirectional changing of these parameters according to cell subset and health status.
Leukemia Research | 1997
Victor I. Seledtsov; G. V. Seledtsova; Elias V. Avdeev; D. M. Samarin; Vladimir A. Kozlov
Hybrid (C56BL/6 x DBA) (BDF1; H-2b/H-2d) mice bearing the P815 leukemia (H-2d) were grafted with a (CBA x C57BL/6)F1 (CBF1; H-2k/H-2b) cell suspension, comprising bone marrow cells (BMC; 25 x 10(6)/mouse) and spleen cells (SC; 55 x 10(6)/mouse) on day-4, then treated with cyclophosphamide (200 mg/kg) on day-2 and finally grafted once more with CBF1 cells (25 x 10(6) BMC + 7 x 10(6) SC) on day 0. Allogeneic cell graftings performed in this way induced durable mixed hematopoietic chimerism and significantly prolonged the survival of recipients, compared with that of leukemia-bearers grafted with syngeneic cells. The results obtained raise the possibility of using allogeneic hematopoietic tissue transplantation in combination with non-lethal cytoreductive therapy to induce a long-lasting graft-vs-leukemia effect.
Cytokine | 2004
Olga P. Yatsenko; M. L. Filipenko; Eugene A. Khrapov; Elena N. Voronina; Vladimir A. Kozlov; Sergey V. Sennikov
Cellular Immunology | 1997
Victor I. Seledtsov; Vadim Ya. Taraban; G. V. Seledtsova; D. M. Samarin; Ilias V. Avdeev; V. V. Senyukov; Vladimir A. Kozlov
The Internet Journal of Anesthesiology | 2006
S. S. Rabinovich; Victor I. Seledtsov; Olga V. Poveschenko; Vladimir V. Senuykov; Vadim Ya. Taraban; Vladimir I. Yarochno; Nicolay G. Kolosov; Sergey A. Savchenko; Vladimir A. Kozlov